8-K: Keros Therapeutics Announces Positive Initial Topline Results from Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics reports successful Phase 1 trial results for KER-065, meeting key safety, tolerability, pharmacokinetic, and pharmacodynamic objectives, supporting its potential for treating Duchenne muscular dystrophy (DMD) and other neuromuscular conditions.

Summary

• Keros Therapeutics announced initial topline results from its Phase 1 clinical trial of KER-065 in healthy volunteers.
• The trial achieved its key objectives for safety, tolerability, pharmacokinetics, and pharmacodynamics.
• KER-065 was generally well-tolerated, with no major safety signals, serious adverse events, or dose-limiting toxicities reported.
• The data showed evidence of activin inhibition across tissues of interest, with increases in bone formation biomarkers (BSAP) and decreases in bone resorption biomarkers (CTX).
• Increases in adiponectin and decreases in leptin were observed, indicating fat mobilization.
• Changes in body composition included increases in bone mineral density and muscle mass, and decreases in fat mass.
• Keros plans to engage with regulatory authorities in the third quarter of 2025.
• Subject to regulatory interactions, Keros expects to initiate a Phase 2 clinical trial of KER-065 in patients with DMD in the first quarter of 2026.

Sentiment

Score: 8

Explanation: The document presents positive initial results from a Phase 1 clinical trial, indicating potential for a new treatment for DMD. The drug was well-tolerated, and the company is moving forward with regulatory discussions and plans for a Phase 2 trial. This suggests a positive outlook for the company and its pipeline.

Positives

• KER-065 was generally well-tolerated in the Phase 1 trial, with no major safety signals, serious adverse events, or dose-limiting toxicities.
• The trial demonstrated evidence of activin inhibition across tissues of interest.
• The data showed increases in bone formation biomarkers (BSAP) and decreases in bone resorption biomarkers (CTX).
• Increases in adiponectin and decreases in leptin were observed, indicating fat mobilization.
• Changes in body composition included increases in bone mineral density and muscle mass, and decreases in fat mass.
• The pharmacokinetic profile of KER-065 was generally consistent with that of a well-behaved biologic, supporting monthly dosing.

Risks

• The forward-looking statements are subject to risks and uncertainties, including Keros' limited operating history and historical losses.
• Keros' ability to raise additional funding to complete the development and commercialization of its product candidates is a risk.
• Keros' dependence on the success of its product candidates, cibotercept, KER-065 and elritercept, poses a risk.
• Delays in initiating, enrolling or completing any clinical trials could impact the timeline.
• Competition from third parties developing products for similar uses is a risk.
• Keros' ability to obtain, maintain and protect its intellectual property is crucial.
• Keros' dependence on third parties in connection with manufacturing, clinical trials and preclinical studies is a risk.

Future Outlook

Keros plans to engage with regulatory authorities in the third quarter of 2025 and, subject to regulatory feedback, initiate a Phase 2 clinical trial of KER-065 in patients with DMD in the first quarter of 2026.

Management Comments

• Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer, stated that the topline results met the key objectives of the Phase 1 clinical trial and provided important insights to inform the development of KER-065 for patients with DMD.
• Jasbir S. Seehra, Ph.D., noted the high unmet need for additional treatments in DMD and the potential of KER-065 to address multiple aspects of the disease.
• Yung H. Chyung, M.D., Chief Medical Officer, stated that the data, coupled with preclinical and mechanistic insights, demonstrate the exciting therapeutic potential of KER-065 in DMD and other neuromuscular disorders.

Industry Context

The announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for neuromuscular diseases like Duchenne muscular dystrophy (DMD). The positive Phase 1 results for KER-065 could position Keros Therapeutics as a potential player in the DMD treatment landscape, which currently includes gene therapies, exon skipping therapies, and glucocorticoids.

Comparison to Industry Standards

• The current treatment landscape for DMD includes therapies such as DuvyzatTM (givinostat), ELEVIDYS, exon skipping therapies, and glucocorticoids.
• DuvyzatTM, an HDAC inhibitor, was approved by the FDA for patients aged 6+, but can cause dose-related thrombocytopenia and other signs of myelosuppression.
• ELEVIDYS received full approval for ambulatory individuals aged 4+ and accelerated approval for non-ambulatory individuals aged 4+ based on micro-dystrophin expression.
• Exon skipping therapies, require weekly intravenous infusions and are approved based on dystrophin production.
• Glucocorticoids help maintain muscle function but have significant negative side effects, including bone loss and weight gain.
• KER-065 aims to address multiple aspects of DMD, including muscle, bone, and fat, potentially offering a more comprehensive treatment approach compared to existing therapies.

Stakeholder Impact

• The positive results could benefit shareholders through potential stock appreciation.
• Employees may experience increased job security and opportunities due to the advancement of the drug candidate.
• Patients with DMD and other neuromuscular diseases could benefit from a new treatment option.
• Positive results could enhance the company's relationships with suppliers and collaborators.
• Successful development of KER-065 could improve the company's creditworthiness and access to capital.

Next Steps

• Keros plans to engage regulators on the design of a Phase 2 clinical trial evaluating KER-065 in patients with DMD in the third quarter of 2025.
• Subject to regulatory feedback, Keros plans to initiate this Phase 2 clinical trial in the first quarter of 2026.

Key Dates

Keywords

KER-065, Duchenne Muscular Dystrophy, DMD, Clinical Trial, Phase 1, Keros Therapeutics, Activin Inhibition, Neuromuscular Diseases, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics